



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment

Citation for published version:

Xintaropoulou, C, Ward, C, Wise, A, Queckborner, S, Turnbull, A, Michie, CO, Williams, A, Rye, T, Gourley, C & Langdon, SP 2018, 'Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment', *BMC Cancer*. <https://doi.org/10.1186/s12885-018-4521-4>

Digital Object Identifier (DOI):

[10.1186/s12885-018-4521-4](https://doi.org/10.1186/s12885-018-4521-4)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

BMC Cancer

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment

Chrysi Xintaropoulou¹, Carol Ward^{1,2}, Alan Wise³, Suzanna Queckborner¹, Arran Turnbull¹, Caroline O Michie⁴, Alistair RW Williams⁵, Tzyvia Rye⁴, Charlie Gourley⁴, Simon P Langdon¹

¹Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, United Kingdom.

²The Royal (Dick) School of Veterinary Studies and Roslin Institute, Easter Bush, Roslin, Midlothian EH25 9RG, United Kingdom

³IOmet Pharma (a wholly owned subsidiary of Merck & Co., Inc., Kenilworth, NJ USA , known as MSD outside the United States and Canada) Nine Edinburgh Bioquarter, Little France Road, Edinburgh EH16 4UX, United Kingdom

⁴Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, United Kingdom

⁵Division of Pathology, University of Edinburgh Medical School, 51 Little France Crescent, Edinburgh EH16 4SA, United Kingdom

Corresponding author: Simon Langdon E-mail: simon.langdon@ed.ac.uk

Abstract

Background: Novel therapeutic approaches are required to treat ovarian cancer and dependency on glycolysis may provide new targets for treatment. This study sought to investigate the variation of expression of molecular components (GLUT1, HKII, PKM2, LDHA) of the glycolytic pathway in ovarian cancers and the effectiveness of targeting this pathway in ovarian cancer cell lines with inhibitors.

Methods: Expression of GLUT1, HKII, PKM2, LDHA were analysed by quantitative immunofluorescence in a tissue microarray (TMA) analysis of 380 ovarian cancers and associations with clinicopathological features were sought. The effect of glycolysis pathway inhibitors on the growth of a panel of ovarian cancer cell lines was assessed by use of the SRB proliferation assay. Combination studies were undertaken combining these inhibitors with cytotoxic agents.

Results: Mean expression levels of GLUT1 and HKII were higher in high grade serous ovarian cancer (HGSOC), the most frequently occurring subtype, than in non-HGSOC. GLUT1 expression was also significantly higher in advanced stage (III/IV) ovarian cancer than early stage (I/II) disease. Growth dependency of ovarian cancer cells on glucose was demonstrated in a panel of ovarian cancer cell lines. Inhibitors of the glycolytic pathway (STF31, IOM-1190, 3PO and oxamic acid) attenuated cell proliferation in platinum-sensitive and platinum-resistant HGSOC cell line models in a concentration dependent manner. In combination with either cisplatin or paclitaxel, 3PO (a novel PFKFB3 inhibitor) enhanced the cytotoxic effect in both platinum sensitive and platinum resistant ovarian cancer cells. Furthermore, synergy was identified between STF31 (a novel GLUT1 inhibitor) or oxamic acid (an LDH inhibitor) when combined with metformin, an inhibitor of oxidative phosphorylation, resulting in marked inhibition of ovarian cancer cell growth.

Conclusions: The findings of this study provide further support for targeting the glycolytic pathway in ovarian cancer and several useful combinations were identified.

Keywords: ovarian cancer, glycolytic pathway, inhibitors, combination strategies, cisplatin, metformin

Background

Ovarian cancer is the 7th most common female cancer worldwide with an estimated 239,000 new diagnoses worldwide each year [1]. Standard treatment of ovarian cancer consists of debulking surgery followed by systemic platinum and taxane-based chemotherapy. Even though platinum-based chemotherapy has a high response rate, it is estimated that approximately 70% of patients will relapse with resistant disease and new treatments are required [2]. High-grade serous ovarian cancer (HGSOC) accounts for approximately 70% of epithelial ovarian cancers while non-HGSOC which includes endometrioid, clear cell, mucinous and low-grade serous ovarian cancer, among others, comprise important subgroups [2].

Many cancer cells rely on glycolysis as their primary source of energy regardless of oxygen availability; the persistence of glycolysis in cancer cells even under aerobic conditions is termed aerobic glycolysis or the Warburg effect. This metabolic alteration in tumours has been extensively demonstrated in a wide variety of cancers and considered a 'hallmark' of advanced malignancy [3-5]. It has been estimated that many tumour cells under aerobic conditions produce up to 60% of their ATP requirement through glycolysis [6, 7]. This 'metabolic reprogramming' is an adaptation to meet the requirements of highly proliferative malignant tissues, providing the precursors needed to support biosynthesis [8, 9]. Furthermore, the metabolic alteration of cancer cells can provide them with a selective advantage for survival and growth in low oxygen tumour microenvironments. As tumours grow and expand away from a functional blood supply, glycolysis is an evolutionary adaptation of cells to survive and thrive in a hypoxic environment [3, 7, 10]. This reliance on glycolysis provides a possible therapeutic opportunity and the enzymes comprising the glycolytic pathway may be potential targets for cancer treatment [6, 10-17]. Several glycolytic inhibitors have emerged as exhibiting promising anticancer activity both *in vitro* and *in vivo* and a number have reached clinical trials [10-13, 16].

Glucose transporter 1 (GLUT1) is the first component of the glycolysis pathway, transporting glucose into the cell, and is up-regulated in many tumour types. High expression has been associated with poor clinical outcome and adverse prognosis [18-20]. STF31 [4-[[[4-(1, 1-Dimethylethyl)phenyl]sulfonyl]amino]methyl]-N-3-pyridinylbenzamide] is a pyridyl-anilino-

thiazole that impairs glycolytic metabolism and binds to the GLUT1 transporter [21]. Based on molecular modelling, STF31 was predicted to interact directly with the central pore of the transporter and was shown to inhibit glucose uptake and induce necrotic cell death selectively in glycolytic cancer cells. *In vivo* efficacy of the compound was also demonstrated [21]. IOM-1190 is a GLUT1 inhibitor that suppresses 2-deoxy-D-glucose (2-DG) uptake and lactate production in A549 lung cancer cells resulting in rapid apoptotic cell death. High affinity for GLUT1 binding of the radiolabelled compound has also been documented [22].

Hexokinase catalyses the first rate-controlling irreversible reaction of the glycolytic pathway; phosphorylating glucose to glucose-6-phosphate coupled with ATP de-phosphorylation. The mitochondrial-bound isoform HKII is considered to play a pivotal role in carcinogenesis and is overexpressed in many tumours [23, 24].

6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase (3PFKFB3), which converts fructose-6-phosphate to fructose-2,6-bisP (F2,6BP), is downstream of HKII. PFKFB3 overexpression has been documented in several tumour types including ovarian cancers [25]. In 2008, Clem *et al* identified a competitive inhibitor of PFKFB3, 3PO, using computational modelling and virtual database *in silico* screening. 3PO [3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one] is a novel small molecule, dipyridinyl-propenone based compound that reduced intracellular F2,6BP levels, glucose uptake and lactate production followed by induction of G2-M phase cell cycle arrest. 3PO treatment suppressed tumour growth *in vivo* in mice bearing leukaemia, lung and breast adenocarcinoma xenografts [26].

Further downstream is the M2 isozyme of pyruvate kinase (PKM2) which catalyses the irreversible conversion of phosphoenolpyruvate (PEP) to pyruvate coupled with ADP phosphorylation and is found overexpressed in various tumour types and plays a pivotal role in carcinogenesis [27, 28].

Lactate dehydrogenase A (LDHA) is the enzyme catalysing the reduction of pyruvate in the final step of the glycolytic pathway. LDHA upregulation has been reported in ovarian cancers when compared to normal tissues [29]. LDHA overexpression is considered to have a crucial role in tumorigenesis and is often associated with poor clinical outcome and resistance to therapy [30-32]. Oxamic acid is an established pyruvate analogue (a structural isostere of pyruvic acid) described as a well characterised substrate-like competitive inhibitor of LDH.

Promising anti-proliferative effects of oxamic acid have been reported *in vitro* in hepatocellular and breast carcinoma cell lines [33-36].

Several successful combinations of glycolytic inhibitors with cytotoxic drugs have recently been identified and glycolytic inhibitors have been demonstrated to resensitise drug-resistant cells to conventional regimens [12, 14, 15, 37-39].

We have previously demonstrated antitumour activity of glycolytic inhibitors against panels of ovarian and breast cancer cell lines [40]. In the present study, we evaluated the levels of expression of four selected glycolytic targets (GLUT1, HKII, PKM2 and LDHA) in a large series of ovarian cancers to investigate possible associations with histological subtype and stage of disease. We have then used four inhibitors to target prime components of the pathway and compared these agents against paired chemosensitive and chemoresistant ovarian cancer cell lines. Novel combinations between cisplatin and paclitaxel with inhibitors of the glycolytic pathway were then investigated and evaluated quantitatively by comparison of their combination indices.

Methods

Study population

Primary Ovarian cancer patients treated at the Edinburgh Cancer Centre between 1991-2006 were retrospectively identified from the Edinburgh Ovarian Cancer Database. Tissues were formalin-fixed and paraffin-embedded. Haematoxylin-eosin stained slides were reviewed by a subspecialist gynaecological pathologist, and histological classification of tumour type confirmed. Three separate Tissue Microarray (TMA) replicates containing cores of 380 ovarian tumours were constructed. The number of samples available for histology and stage analysis is shown in Supplementary Table 1 and the full dataset used for analysis is given in Additional File 1.

No informed consent was obtained for use of retrospective tissue samples from the patients within this study, most of whom were deceased, since this was not deemed necessary by the Ethics Committee. The TMA material was kindly provided by the Edinburgh Experimental

Cancer Medicine Centre (ECMC ID: SR319). Ethical approval for the use of tumour material and correlation with associated clinical data was obtained from South East Scotland Human Annotated Bioresource (East of Scotland Research Ethics Service Reference 15/ES/0094).

Immunofluorescence of clinical ovarian cancer tissues

Microscope slides of TMA sections were deparaffinised and rehydrated followed by heat-induced antigen retrieval being performed in sodium citrate buffer at pH6. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 10min and non-specific binding was blocked by a 10min incubation in serum-free protein block (DAKO). Primary antibodies were diluted in antibody diluent (DAKO) and were applied overnight at 4°C. The following primary rabbit antibodies, validated for the protocol, were used: GLUT1 (Merck Millipore), HKII (Cell Signaling Technology), LDHA (Cell Signaling Technology) and PKM2 (Cell Signaling Technology). The following day, tissue sections were washed with 0.05% PBS Tween 20 (PBS-T), and were then incubated with primary mouse anti-cytokeratin antibody (M3515/DAKO) diluted 1:25 in the same antibody diluent in order to mask the tumour areas. This incubation was performed at room temperature, lasted 1h and was followed by PBS-T washes. To enable epithelial mask visualisation, slides were then incubated with the secondary goat anti-mouse antibody conjugated with Alexa Fluor 555 (Thermo Fisher Scientific) diluted 1:25 in the goat anti-rabbit peroxidase-conjugated Envision reagent (DAKO). This incubation was conducted at room temperature protected from light for 90 min and was followed by PBS-T washes. Target visualisation was implemented by a 10min incubation with Cyanine 5 (Cy5) Tyramide, diluted at 1:50 in amplification diluent (PerkinElmer), at room temperature protected from light. Subsequently, tissue sections were washed with PBS-T and dehydrated. Finally, slides were counterstained with 45µl Prolong Gold Antifade Mountant with DAPI (4', 6-diamidino-2-phenylindole) (Thermo Fisher Scientific) to visualise the nuclei and a coverslip was mounted.

AQUA Image Analysis

Protein expression in the ovarian tumour cores was quantitatively evaluated by Automated Quantitative Analysis (AQUA) [41]. High resolution monochromatic images of each TMA core were captured at 20x objective using an Olympus AX-51 epifluorescence microscope and were analysed by AQUAnalysis software. DAPI, Cy-3 and Cy-5 filters were applied to visualise the nuclei, the cytokeratin tumour mask and the target protein respectively. The Cy-5 fluorescent signal intensity of the target antigen was quantified in each image pixel. A quantitative score was attributed to each histospot based on the average Cy5 signal in the cytoplasmic compartment within the epithelial tumour mask, as identified by the cytokeratin Cy3 stain. Damaged cores or cores containing imaging errors as well as those consisting of less than 5% epithelium were excluded from further analysis.

Target expression in the cytoplasmic compartment of each core was quantified and assigned an AQUA score. Data were filtered and only samples that had at least two replicate values were considered. Expression values were averaged from either two or three replicates. Spearman non-parametric correlation and network analysis were conducted using TMA Navigator [42]. Correlation heatmaps were generated using the same software (<http://www.tmanavigator.org/>). For this analysis, expression data of different markers had been log₂ transformed, mean-centred and quantile-normalised to compensate for differences in the staining. The expression of examined glycolytic targets was compared across the different pathological stages and histological types of ovarian tumours using one-way ANOVA and statistical significance was determined by the Tukey's multiple comparisons test. The Spearman correlation coefficient was calculated for each pair of markers and statistical significance was determined using the Algorithm AS89 [43]. Spearman's correlation P-values were adjusted for multiple hypothesis testing according to Benjamini-Yekutieli FDR correction. The P-value significance threshold was set at 0.01.

Cell lines

A panel of four ovarian cancer cell lines were used initially. OVCAR5, OVCAR3 and CAOV3 are HGSOE cell lines [44] while TOV112D is of endometrioid ovarian cancer origin [45]. OVCAR5

and OVCAR3 were gifts from Dr Tom Hamilton, Fox Chase Institute, Philadelphia, PA USA while CAOV3 and TOV112D were obtained from American Type Culture Collection, Manassas, Virginia, USA. Two cell line pairs derived from two patients with HGSOC at different stages of platinum-based chemotherapy were also used – PEA1 / PEA2 and PEO1/PEO4 respectively [46]. The first cell line of each pair was regarded as chemosensitive and the second cell line (which was isolated following the development of platinum resistance), chemoresistant [46, 47]. These were developed within our laboratory and are now available at the European Collection of Cell Cultures, Porton Down, UK. All cell lines used in this study were authenticated using Short Tandem Repeat profiling (STR) (by ECACC) and were routinely subjected to mycoplasma testing.

Cell culture

All cell line work was conducted in sterile conditions in a class II Laminar Air Flow hood at room temperature. Cells were incubated in a humidified atmosphere of 5% CO₂ at 37°C. The panel of four ovarian cancer cell lines (OVCAR5, TOV112D, OVCAR3 and CAOV3) were all maintained in Dulbecco's Modified Eagle Medium without HEPES modification (DMEM, Thermo Fisher Scientific), containing glucose (5.56mM), Sodium Pyruvate (1mM) and L-glutamine (3.97mM). The two ovarian cancer cell line pairs (PEA1-PEA2, PEO1-PEO4) were maintained in RPMI 1640 (Thermo Fisher Scientific) containing 11.11mM glucose and 2mM L-glutamine. In both cases the media contained phenol red and were supplemented with 10% heat inactivated fetal bovine serum FBS (Fetal Bovine Serum, Thermo Fisher Scientific) and 1% Penicillin-Streptomycin (Penicillin-Streptomycin 10,000 U/mL, Thermo Fisher Scientific).

In the deprivation experiments where the effect of glucose availability on cell growth of different cell lines was examined, medium without glucose was used (DMEM, Thermo Fisher Scientific). Phenol red free media were supplemented with 10% heat inactivated dialysed fetal bovine serum (Thermo Fisher Scientific) and 1% Penicillin-Streptomycin. In the glucose depleted medium the desired concentration of D-Glucose (Sigma Aldrich) was added along with a standard 4mM L-Glutamine (Sigma Aldrich) concentration.

Cells were routinely maintained in T175cm³ tissue culture flasks and were sub-cultured at least once a week, when reaching 70-80% confluence as described below. Medium was discarded and cells were washed with preheated phosphate buffered saline. Cells were then incubated for a few minutes with a trypsin/EDTA solution (Trypsin-EDTA 0.05%, Thermo Fisher Scientific) to cause cell detachment and cell suspension was centrifuged at 1,200rpm for 5min. Pelleted cells were resuspended in fresh media and transferred into new flasks. When setting up an experiment cells were counted using a Neubauer hemocytometer and were seeded in cell culture plates or dishes at the desired dilution.

Sulphorhodamine B assay (SRB)

The SRB assay is a colorimetric cell density assay based on the quantification of cellular protein content [48]. Cells were seeded in flat-bottom 96-well plates. After 48h incubation, cells were treated with or without the relevant treatment as indicated. STF31 and metformin were obtained from Tocris Bioscience, 3PO from Merck Millipore and oxamic acid from Sigma Aldrich. IOM-1190 was provided by IOMET Pharma. The compound is example 187 in patent WO2014/187922 and has an imidazo pyrazine core [49].

Cisplatin (Teva UK Limited) and paclitaxel (Actavis) were obtained as formulated drugs. Stock solutions of compounds were prepared in DMSO except for oxamic acid and metformin which were dissolved in PBS. A series of 10 dilutions with 1:2 steps of each inhibitor in six replicates was applied. Once the treatment period was completed, cell monolayers were fixed on the day of treatment (Day 0 control) and on selected time points thereafter with cold 25% trichloroacetic acid (TCA, Sigma Aldrich). Then cell monolayers were stained with 0.4% SRB dye solution (Sigma Aldrich) and unbound excess dye was removed by 1% glacial acetic acid (VWR International) washes. The protein bound stain was solubilised in 10mM Tris buffer solution pH 10.5 (Sigma Aldrich). Finally absorbance was measured at 540nm using a plate reader.

Measurements were corrected for background absorbance and values are presented as percentage of absorbance of untreated control. The half maximal inhibitory concentration (IC_{50}), indicating the concentration needed to reduce cell viability by half, was used as a quantitative indication of the effectiveness of each compound as a cancer cell growth inhibitor. IC_{50} values were generated through sigmoidal concentration response curves fitted using the XL fit tool within Microsoft Excel.

Combinatorial treatments

In combination drug studies, glycolytic inhibitors were assessed in combination with traditional drugs. For these treatments a range of different concentrations of the glycolytic inhibitor were combined with a constant fixed concentration, around the IC_{20} or less, of the other drug. Both drugs were delivered at the same time and cancer cell proliferation was examined by the SRB assay after a 3-day treatment period. Concentration response curves of each examined combination along with curves of the two compounds as single agents were analysed using CalcuSyn Software (Biosoft). To quantitatively evaluate the effectiveness of each combination, CI values were generated for each combination point indicating synergy, additivity or antagonism [50]. CI values lower than 0.8 indicate synergy, values between 0.8 and 1.2 imply additivity while values higher than 1.2 indicate antagonism [50].

Statistical Analysis

Statistical tests were undertaken using GraphPad Prism software version 6. Student's t-test was used to compare two groups and ANOVA followed by the Tukey post-test was used to compare more than two groups. For survival analysis, we undertook Kaplan Meier analysis using X-tile [51] which allows determination of the minimal p-value using the Miller-Siegmund minimal P correction.

Results

Expression of glycolytic enzymes in ovarian tumours and association with histological subtypes and stage

To assess the variation in expression of key components of the glycolytic pathway in ovarian cancers, expression levels of GLUT1, HKII, PKM2 and LDHA were investigated in a series of 380 ovarian tumours by Automated Quantitative Analysis (AQUA). A three label immunofluorescent protocol was used generating a quantitative score for each tumour core. Representative immunofluorescence images illustrating the expression of the four glycolytic targets in TMA cores of ovarian cancers are shown in Figure 1A-1D. GLUT1 showed membrane as well as cytoplasmic localisation while HKII, PKM2 and LDHA demonstrated cytoplasmic localisation (Figure 1A-1D). In Figure 1E, the expression of the four proteins is shown for an individual ovarian cancer case illustrating high expression for all four consistent with a glycolytic phenotype.

Associations between the level of expression of the four molecules and the histological subtype of ovarian cancer were then examined (Figure 2). High-grade serous ovarian cancer (HGSOC) accounts for approximately 70% of epithelial ovarian cancers [2] and was first compared with non-HGSOC disease. Mean expression of GLUT1 was higher in HGSOC than in non-HGSOC samples ($P=0.0011$; t-test) (Figure 2A). Similarly, HKII expression was higher in HGSOC than non-HGSOC ($P=0.031$; t-test) and this was reflected in a difference between HGSOC and clear cell disease ($P<0.05$; Tukey test post ANOVA) (Figure 2B). In contrast, LDHA expression was lower in HGSOC than in non-HGSOC ($P=0.022$; t-test) and again this difference was reflected in HGSOC being lower than clear cell ($P<0.01$; Tukey test post ANOVA) (Figure 2C). For PKM2, there were no statistically significant differences between the histological subtypes (Figure 2D).

When stage of disease was analysed, GLUT1 expression was higher in advanced disease (stages III/IV) than early disease (stages I/II) ($P=0.023$; t-test) (Figure 3). In contrast, LDHA expression was lower in Stage IV than stage I disease ($P<0.05$; Tukey test post ANOVA) (Figure 3) while no obvious differences emerged for HKII or PKM2. Analysis of the HGSOC group alone indicated no differences in expression between advanced and early stage HGSOC (data not shown). Analysis of patient survival using x-Tile optimal cut-point analysis [51] showed no

significant differences in survival with varying expression levels of the four molecules in any of the HGSOC, endometrioid or clear cell cancer groups (data not shown).

A heatmap correlating the expression of the four examined glycolytic enzymes across the dataset is shown in Figure 4A. Spearman non-parametric correlation was performed and the correlation heatmap was generated using TMA Navigator [43]. The expression of the four targets across the ovarian cancers gave positive rho correlation values when compared to each other. Based on the dendrogram, LDHA expression appeared more closely correlated with PKM2 expression; in contrast HKII expression was more distant to the expression of the other three markers. Spearman correlation network analysis was conducted to further interpret the relationship between the glycolytic markers and evaluate their associations. The correlation network of expression of the four glycolytic enzymes is presented in Figure 4B. Significant relationships (FDR $P < 0.01$) are drawn as lines that connect pairs of markers. Thickness of connection lines reflects significance and positive significant relationships are displayed in grey colour. The colour of each marker indicates the number of significant connections. High number of significant connections is displayed in yellow colour while low in blue. The correlation values (FDR $P < 0.01$) are summarised in Supplementary Table 2.

The effect of glucose on cell growth of a panel of ovarian cancer cell lines

To assess the growth dependence of ovarian cancer cells on glucose, the proliferation of a small panel of ovarian cancer cell lines was monitored under a range of glucose concentrations after a 5-day incubation period. Growth was compared with controls in medium without glucose. Figure 5 illustrates the average optical density value generated via SRB assay (indicative of cell number) against increasing concentration of glucose. OVCAR5, CAOV3 and OVCAR3 are of HGSOC origin [45] while TOV112D is of endometrioid cancer origin [46]. OVCAR5 and CAOV3 cells were unable to proliferate when cultured in the absence of glucose for five days; 0.2mM of glucose was required for significant growth of OVCAR5 cells with higher concentrations leading to higher growth rate until a plateau was reached at 1.6mM glucose. CAOV3 cells demonstrated significant growth, in comparison to the control samples, when cultured in a minimum of 0.4mM glucose. In contrast, OVCAR3 and TOV211D

cells showed a threefold increase in their cell number in the absence of glucose however were still able to grow more rapidly in the presence of added glucose (Figure 5).

The effect of glycolytic inhibitors on cell growth of chemosensitive and chemoresistant HGSOC ovarian cancer cell lines

PEA1 / PEA2 and PEO1 / PEO4 are two pairs of cancer cell lines established from two individual patients with HGSOC [47]. The first cell line of each pair is platinum sensitive (PEA1 and PEO1 respectively) while the second line (PEA2 and PEO4 respectively) was acquired after platinum resistance had developed within the patient [47, 48]. Four glycolytic inhibitors (IOM-1190, STF31, 3PO and oxamic acid) were investigated against these ovarian cancer cell line pairs (Figure 6) and IC₅₀ concentrations are listed in Table 1. These inhibitors were selected based on interest in targeting GLUT1 at the top and LDHA at the bottom of the pathway and also on preliminary evidence that the PFKFB3 inhibitor, 3PO, had interesting combinatorial activity in pilot experiments.

IOM-1190 is a novel specific GLUT1 inhibitor [22] and attenuated cell proliferation of both chemosensitive and chemoresistant cell lines. PEA1 had an IC₅₀ value equal to 280nM and PEA2 equal to 460nM. In contrast, the PEO4 platinum-resistant cell line presented greater sensitivity having a threefold lower IC₅₀ value (equal to 1.6μM) compared to the platinum sensitive PEO1 cell line (4.8 μM). STF31, another GLUT1 inhibitor [21] had similar inhibitory activity against both cell lines of each pair. Although also reported as an NAMPT inhibitor [52], it reassuringly had a pattern of activity similar to that of IOM-1190. The PEA2 cell line was slightly more resistant to STF31 compared to its paired platinum naïve line PEA1, with IC₅₀ values of 1.3μM and 0.9μM respectively. In contrast, the platinum-resistant line PEO4, having an IC₅₀ value of 0.9μM, showed increased sensitivity to the inhibitor compared to its paired platinum-sensitive line PEO1, with an IC₅₀ value of 1.5μM. 3PO is a recently identified PFKFB3 inhibitor [27]. Sensitivity to 3PO coincided with platinum sensitivity. Both platinum resistant cell lines (PEA2 and PEO4) presented greater resistance to 3PO compared to their platinum sensitive paired cell lines with twofold higher IC₅₀ value. Oxamic acid is an established LDH inhibitor [34-37]. The first ovarian cancer cell line pair responded similarly to this agent with an almost identical IC₅₀ value of 16mM. Regarding the second pair, the PEO4 platinum

resistant cell line proved to be more resistant to oxamic acid, having an IC_{50} value threefold higher than the corresponding value of PEO1 (Table 1). These results indicate that, in general, platinum-resistant disease has comparable sensitivity to these glycolysis inhibitors when compared to chemo-sensitive disease.

The PFKFB3 inhibitor, 3PO, potentiated the antiproliferative effect of cisplatin and paclitaxel in ovarian cancer cells

Combinations of the PFKFB3 inhibitor, 3PO, with cisplatin and paclitaxel were next investigated against the paired cell lines. 3PO was able to enhance the effect of cisplatin in both the chemosensitive PEA1 and chemoresistant PEA2 cell lines. A range of different concentrations of 3PO were used in combination with a constant fixed concentration (around the IC_{20}), of the cytotoxic drug; hence in PEA2 cells, 4 μ M of cisplatin was required to produce a similar inhibitory effect in cell number to that of 1 μ M cisplatin on PEA1 cells. Both drugs were delivered at the same time and cancer cell proliferation was examined by the SRB assay after a 3-day treatment period. Combination Index values (CI) were generated for each combination point, using Calcosyn software, providing a quantitative evaluation of the combination efficacy. Concentrations at which synergistic interactions (CI values lower than 0.8) between the two compounds were identified are indicated by asterisks in Figure 7A. The combination of 3PO with paclitaxel was also effective in inhibiting growth of the PEA1 and PEA2 cell lines, generating low CI values for all 3PO concentrations used (Figure 7.B). These drug combinations were similarly effective for the other examined ovarian cancer cell line pair PEO1 and PEO4 and also demonstrated synergistic activity (Supplementary Figure 1).

Metformin potentiated the antiproliferative effect of glycolytic inhibitors on ovarian cancer cells

We have previously reported promising combinatorial activity between metformin and STF31 or oxamic acid in a breast cancer cell line [40]. Metformin inhibits the mitochondrial respiratory chain complex I and combination with a glycolytic inhibitor will result in more complete depletion of cellular ATP. The effect of either STF31 or oxamic acid on both chemosensitive and chemoresistant ovarian cancer cell lines was markedly enhanced by metformin (Figure 7.C). Strong synergy at the level of a CI value equal to 0.1 was

demonstrated for both cell lines. These drug interactions were similarly effective for the other examined ovarian cancer cell line pair (PEO1-PEO4, Supplementary Figure 1C).

Discussion

There is continued interest in the potential of targeting the glycolytic pathway as a therapeutic strategy for cancer treatment [15, 17, 45, 46]. In this study we evaluated the relative expression of several glycolytic markers across a large cohort of clinical ovarian tumours by use of *in situ* immunofluorescence staining. We are not aware of any previous study which has reported the expression of multiple glycolytic enzymes in ovarian tumours and certainly none that include a cohort of this size.

Analysis of histological subtype indicated higher expression of GLUT1 in HGSOC, the most frequently occurring form of epithelial ovarian cancer. Previous studies in small series of tumours have demonstrated increasing GLUT1 expression when comparing ovarian benign and borderline tumours to malignant ovarian adenocarcinomas and this transporter has been suggested as a potential marker of ovarian malignancy [53, 54, 55]. Our data is in line with a number of studies which have documented elevated GLUT1 expression in serous adenocarcinomas [54, 56-58]. Significantly higher GLUT1 expression was detected in advanced stage (III/IV) tumours compared to early stage (I/II) cancers. This is consistent with a previous report of increased GLUT1 expression being higher in advanced stage ovarian tumours [56]. GLUT1 has been proposed as a marker of adverse prognosis in ovarian cancer, however we did not observe an effect on survival in this cohort of patients [58]. Cantuaria *et al* associated GLUT1 overexpression with poor disease free survival rate in 89 advanced stage ovarian carcinomas [59] while Semaan *et al* demonstrated that high GLUT1 expression had a negative impact on the overall survival of 213 ovarian cancer patients [57]. Consistent with these reports, Cho *et al* described a reverse statistically significant association among overall survival of 50 patients and high GLUT1 expression [58]. Enhanced tracer [¹⁸F]-fluorodeoxyglucose (FDG) uptake, quantified by PET, has been shown to relate to increased GLUT1 expression in ovarian cancer and was related to increased cellular proliferation [60].

As for GLUT1, we observed that HKII was increased in HGSOC relative to non-HGSOC. The mitochondrial-bound HKII is the predominant isoform expressed in many tumours. Increased

HKII expression has been noted in ovarian cancer for malignant tumours compared to benign and borderline tumours and increased HKII expression in serous carcinomas was found compared to non-serous tumours [61]. Suh *et al* examined HKII expression by IHC in 111 ovarian tumours and documented that high HKII was correlated with chemoresistance and disease recurrence as well as decreased progression free survival [62].

The dependence of ovarian cancer cell growth on glucose was next assessed by investigating the effect of varying glucose concentration in culture. The mean physiological level of glucose in the plasma is approximately 5mM, with a maximum concentration of 9mM after eating and a minimum of 3mM following physical exercise or moderate fasting [63]. Frequently the concentration of glucose in malignant tissues is significantly lower (up to 10 fold) than their normal counterparts in consequence of augmented glucose consumption and abnormal tumour microvasculature [64]. The ovarian cancer cell lines demonstrated differential ability to grow in the absence of glucose. TOV112D and OVCAR3 were both able to increase their cell number up to threefold in glucose depleted conditions while in contrast OVCAR5 and CAOV3 were unable to grow when glucose was not present in the culture medium (Figure 5). For CAOV3 cells, a relatively high concentration equal to 0.4mM was required for significant growth. Interestingly OVCAR5, TOV112D and CAOV3 cells reached a plateau of maximal growth at 1.6mM glucose. In contrast, OVCAR3 cells demonstrated optimal growth when cultured in a low glucose environment of 0.4mM. Glucose deprivation has been extensively associated with oxidative stress [65, 66]. Aykin-Burns *et al* attributed the increased sensitivity of breast cancer cells to glucose withdrawal (and subsequently to glucose inhibition) compared to normal mammary epithelial cells, to the pro-oxidant status mediated by elevated ROS production [66]. In line with these findings Graham *et al* also confirmed the association between the metabolic reconfiguration of tumours and increased sensitivity to glucose deprivation. They linked glucose depletion with elevated tyrosine kinase signalling and ROS mediated cell death [67].

In a previous report, we provided evidence that nine compounds targeting key components of the glycolytic pathway inhibited cancer cell proliferation in a concentration-dependent manner [40]. To explore this further, the effects of several inhibitors targeting key enzymes of the glycolytic pathway were investigated against paired chemosensitive/chemoresistant HGSOC cell line models. Recent evidence has associated drug resistance with an elevated

dependency on the glycolytic phenotype however much less is known as to whether glycolysis inhibition could be exploited against resistant disease [68]. Targeting three major components of glycolysis proved effective in attenuating ovarian cancer cell proliferation in a concentration-dependent manner regardless of platinum sensitivity. The recently developed agents, IOM-1190, STF31 and 3PO were considerably more potent in inhibiting cancer cell proliferation compared to the more established oxamic acid that required concentrations in the millimolar concentration range (Table 1).

Currently, the administration of antitumour therapy generally involves combinatorial strategies of several therapeutic agents. Drug combinations aim to augment the therapeutic benefit, reduce the adverse effects and delay or ideally hinder resistance. Resistance to common chemotherapeutic agents has been associated with the deregulated reliance of tumours on the glycolytic pathway. It has been suggested that targeting the metabolic phenotype of tumours may enhance the efficacy of chemotherapy regimens and moreover resensitise tumour cells to treatment to which they had developed resistance [39, 40]. Possible proposed mechanisms predict glycolysis inhibition reducing cellular ATP levels and compromising the activation of resistance pathways or attenuating tumour growth promoting induction of apoptosis and hindering the adaptation to chemotherapeutic treatment [39, 40].

Platinum-based drugs are the most widely used agents for the treatment of ovarian cancer however platinum-refractory disease frequently develops and hence combinatorial treatments with other antitumour agents are currently under investigation, aiming to alleviate adverse effects and overcome resistance [69]. We observed that the PFKFB3 inhibitor 3PO significantly enhanced the cytotoxic effect of cisplatin against both platinum sensitive and platinum resistant ovarian cancer cells. This supports the view that combinatorial treatment of cisplatin with 3PO could reverse the platinum resistant phenotype and may be an effective strategy against platinum-resistant ovarian tumours. It should be noted that the concentrations of the two drugs that gave the lowest CI values are relatively low and potentially achievable in *in vivo* experiments. Paclitaxel (given 3-weekly) along with carboplatin is the other first line treatment for ovarian cancer. In addition, paclitaxel is also often used in a weekly schedule in platinum resistant disease. 3PO combined with paclitaxel produced synergistic anticancer action on ovarian cancer cells. Both PEA1 and PEA2 cell lines

were very sensitive to this combination and the effectiveness of this combination especially for the resistant PEA2 line suggests that this combination might have *in vivo* potential.

To date a number of studies have revealed that certain compounds targeting the glycolytic metabolism of tumours might improve the therapeutic index of chemotherapeutic cytotoxic agents mainly through reduction of the ATP levels selectively in malignant cells [39, 40]. Similar to this study's observations Liu *et al* reported synergistic antitumour action between the GLUT1 inhibitor WZB117 and cisplatin or paclitaxel [70]. Another glucose transport inhibitor, the phytochemical Phloretin, has been shown to potentiate the cytotoxic effect of daunorubicin promoting apoptosis and also sensitised resistant leukaemia and colon cancer cells to the anthracycline exclusively under hypoxic conditions [71]. Nakano *et al* documented that the HKII inhibitor 3BP enhanced the anticancer effects of daunorubicin and doxorubicin in leukaemia and myeloma cells both *in vitro* and *in vivo*. The glycolytic inhibitor diminished the cellular ATP levels which led to inactivation of the ATP-binding cassette transporters (ABC) therefore preventing the agent's efflux from malignant cells [72].

Metformin is a biguanide widely used for the treatment of type 2 diabetes mellitus. The drug reduces insulin resistance and blood glucose levels through inhibition of mitochondrial respiratory chain complex 1 leading to reduced ATP production and subsequently provoking AMPK activation and mTOR inhibition [73, 74]. A considerable number of epidemiologic meta-analyses have associated metformin with a decreased incidence of several malignancies as well as with improved clinical outcome and reduced cancer-related mortality of diabetic cancer patients. Anti-proliferative action has been extensively demonstrated in preclinical studies in several types of cancer [72-77] and metformin is an attractive candidate for combinatorial cancer treatment. Experimentally, metformin enhanced the cytotoxic effect of several agents including cisplatin, paclitaxel and doxorubicin [73, 79, 80]. Metformin is currently being assessed in numerous clinical trials in various cancer types as chemoprevention, monotherapy or in combination with several chemotherapeutic agents [73-78]. However, to date little attention has been paid to a possible interaction among glycolytic inhibitors and the antidiabetic drug. We previously reported a beneficial interaction between the glycolytic inhibitors STF31 and oxamic acid when combined with metformin in a triple negative breast cancer cell line model [40]. In the present study, we observed that metformin augmented STF31 and oxamic acid-induced cytotoxicity in both platinum sensitive

and platinum resistant ovarian cancer cells. It was observed that while low concentrations of the antidiabetic drug and the glycolytic inhibitors had only marginal effects on the growth of ovarian cancer cell lines, in combination they induced a marked antitumour effect characterised by low synergistic CI values. This data extends our previous findings obtained in a breast cancer model [40] and provides further evidence that suggests that dual inhibition of the two energy pathways might be a promising antitumour therapeutic strategy for ovarian, as well as breast, cancer. Further research should now be undertaken to validate these promising *in vitro* pilot data and investigate their *in vivo* therapeutic potential.

Conclusions

To the best of our knowledge this is the first study evaluating the expression of a series of glycolytic enzymes in a large cohort of ovarian tumours. We observed that HGSOC and advanced stage tumours frequently express higher levels of GLUT1 and HKII, the initial components of the pathway. Cell lines from HGSOC that are resistant to cytotoxic treatment retain comparable sensitivity to glycolytic inhibitors. Combination of glycolytic inhibitors with chemotherapy can produce significantly increased growth inhibition. This study supports further consideration of the use of glycolytic inhibitors for the treatment of ovarian cancer.

List of Abbreviations

AQUA: automated quantitative analysis; **CI**: combination index; **Cy3**: cyanine 3; **DAPI**: 4',6-diamidino-2-phenylindole; **2-DG**: 2-Deoxy-D-glucose; **DMEM**: Dulbecco's modified Eagle's medium; **EDTA**: ethylenediaminetetraacetic acid; **FBS**: fetal bovine serum; **FDR**: false discovery rate; **GLUT1**: glucose transporter 1; **HGSOC**: high grade serous ovarian cancer; **HKII**: hexokinase II; **IC₅₀**: half maximal inhibitory concentration; **IHC**: immunohistochemistry; **IOM**:

1190: IOMET 1190; **LDHA** : lactate dehydrogenase A; **PBS:** phosphate buffered saline; **PEP:** phosphoenolpyruvate; **PET:** positron emission tomography; **PFK1:** phosphofructokinase 1; **PFKFB3:** 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3; **PKM2:** M2 isozyme of pyruvate kinase; **3PO:** 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one; **ROS:** reactive oxygen species; **SRB:** sulphorhodamine B; **STF31:** 4-[[[4-(1,1-Dimethylethyl)phenyl]sulfonyl]amino]methyl]-N-3-pyridinylbenzamide; **STR:** short tandem repeat profiling; **TCA:** trichloroacetic acid; **TMA:** tissue microarray.

Declarations

Acknowledgements

We thank ECMC for access to the tissue microarrays and the Edinburgh Ovarian Cancer Database for help with the data collection.

Funding

We are grateful to Medical Research Scotland and METOXIA (HEALTH-F2-2009-222741) for support of the present study. The funding bodies did not influence the study design, manuscript preparation, data collection, analysis or interpretation.

Availability of data and material

All data generated or analysed during this study are included in this published article and its supplementary information files.

Author's contributions

CX and SQ were responsible for data collection and analysis; CX and SPL drafted the manuscript; CX, CW, AW and SPL participated in the design of the study; AT participated in

the bioinformatics analysis; CG, COM, TR and ARW contributed to the design of the tissue microarray. All authors read and approved the manuscript.

Ethics approval and consent to participate

No informed consent (written or verbal) was obtained for use of retrospective tissue samples from the patients within this study, most of whom were deceased, since this was not deemed necessary by the Ethics Committee. Ethical approval for the use of tumour material and correlation with associated clinical data was obtained from South East Scotland Human Annotated Bioresource (East of Scotland Research Ethics Service Reference 15/ES/0094). Under the Human Tissue (Scotland) Act 2006, established human cell lines are not considered relevant material as all the original cells from the person have been replaced by cells that have divided and therefore have been created outside the human body. As such their use in this research study did not require authorisation (consent) or ethical approval

Consent for publication

Not applicable

Competing interests

AW is an employee of IOmet Pharma.

References

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2014.
2. Hollis RL, Gourley C. Genetic and molecular changes in ovarian cancer. *Cancer Biology and Medicine*. 2016; 13: 236 - 247.
3. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. *Cell*. 2008; 134: 703-707.

4. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. *Cell*. 2011; 144: 646-674.
5. Ward PS, Thompson CB. Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate. *Cancer Cell*. 2012; 21: 297-308.
6. Yeluri S, Madhok B, Prasad KR, Quirke P, Jayne DG. Cancer's craving for sugar: An opportunity for clinical exploitation. *Journal of Cancer Research and Clinical Oncology*. 2009; 135: 867-877.
7. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? *Nature Reviews Cancer*. 2004; 4: 891-899.
8. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation. *Cell Metabolism*. 2008; 7: 11-20.
9. Heiden MG, Cantley LC, Thompson CB. Understanding the warburg effect: The metabolic requirements of cell proliferation. *Science*. 2009; 324: 1029-1033.
10. Granchi C, Fancelli D, Minutolo F. An update on therapeutic opportunities offered by cancer glycolytic metabolism. *Bioorganic and Medicinal Chemistry Letters*. 2014; 24: 4915-4925.
11. Chen Z, Lu W, Garcia-Prieto C, Huang P. The Warburg effect and its cancer therapeutic implications. *Journal of Bioenergetics and Biomembranes*. 2007; 39: 267-274.
12. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. *Oncogene*. 2006; 25: 4633-4646.
13. Madhok BM, Yeluri S, Perry SL, Hughes TA, Jayne DG. Targeting glucose metabolism: An emerging concept for anticancer therapy. *American Journal of Clinical Oncology*. 2011; 34: 628-635.
14. Gatenby RA, Gillies RJ. Glycolysis in cancer: A potential target for therapy. *International Journal of Biochemistry and Cell Biology*. 2007; 39: 1358-1366.
15. Zhao Y, Liu H, Riker AI, Fodstad O, Ledoux SP, Wilson GL, Tan M. Emerging metabolic targets in cancer therapy. *Frontiers in Bioscience*. 2011; 16: 1844-1860.
16. Tennant DA, Durán RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. *Nature Reviews Cancer*. 2010; 10: 267-277.
17. Vander Heiden MG. Targeting cancer metabolism: A therapeutic window opens. *Nature Reviews Drug Discovery*. 2011; 10: 671-684.

18. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. *Journal of Cellular Physiology*. 2005; 202: 654-662.
19. Szablewski L. Expression of glucose transporters in cancers. *Biochimica et Biophysica Acta - Reviews on Cancer*. 2013; 1835: 164-169.
20. Aparicio LA, Calvo MB, Figueroa A, Pulido EG, Campelo RG. Potential role of sugar transporters in cancer and their relationship with anticancer therapy. *International Journal of Endocrinology*. 2010; 2010:
21. Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A, Reynolds GE, Chi JT, Wu J, Solow-Cordero DE, Bonnet M, Flanagan JU, Bouley DM, et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. *Science Translational Medicine*. 2011; 3: 94ra70
22. Wise A, *Identification of novel inhibitors of GLUT1 as potent cancer cell-killing agents*, in *26th EORTC-NCI-AACR Symposium* 2014: Barcelona, Spain.
23. Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. *Oncogene*. 2006; 25: 4777-4786.
24. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH. Mitochondrial bound type II hexokinase: A key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. *Biochimica et Biophysica Acta - Bioenergetics*. 2002; 1555: 14-20.
25. Atsumi T, Chesney J, Metz C, Leng L, Donnelly S, Makita Z, Mitchell R, Bucala R. High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. *Cancer Research*. 2002; 62: 5881-5887.
26. Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, Rasku MA, Arumugam S, Dean WL, Eaton J, Lane A, Trent JO, Chesney J. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. *Molecular Cancer Therapeutics*. 2008; 7: 110-120.31.
27. Iqbal MA, Gupta V, Gopinath P, Mazurek S, Bamezai RNK. Pyruvate kinase M2 and cancer: An updated assessment. *FEBS Letters*. 2014; 588: 2685-2692.
28. Wong N, Ojo D, Yan J, Tang D. PKM2 contributes to cancer metabolism. *Cancer Letters*. 2015; 356: 184-191.

29. Koukourakis MI, Kontomanolis E, Giatromanolaki A, Sivridis E, Liberis V. Serum and tissue Idh levels in patients with breast/gynaecological cancer and benign diseases. *Gynecologic and Obstetric Investigation*. 2009; 67: 162-168.
30. Fiume L, Manerba M, Vettraiño M, Di Stefano G. Inhibition of lactate dehydrogenase activity as an approach to cancer therapy. *Future Medicinal Chemistry*. 2014; 6: 429-445.
31. Miao P, Sheng S, Sun X, Liu J, Huang G. Lactate dehydrogenase a in cancer: A promising target for diagnosis and therapy. *IUBMB Life*. 2013; 65: 904-910.
32. Augoff K, Hryniewicz-Jankowska A, Tabola R. Lactate dehydrogenase 5: An old friend and a new hope in the war on cancer. *Cancer Letters*. 2015; 358: 1-7.
33. Fiume L, Manerba M, Vettraiño M, Di Stefano G. Impairment of aerobic glycolysis by inhibitors of lactic dehydrogenase hinders the growth of human hepatocellular carcinoma cell lines. *Pharmacology*. 2010; 86: 157-162.
34. Fiume L, Vettraiño M, Manerba M, Di Stefano G. Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors. *Pharmacological Research*. 2011; 63: 328-334.
35. Zhao Y, Liu H, Liu Z, Ding Y, LeDoux SP, Wilson GL, Voellmy R, Lin Y, Lin W, Nahta R, Liu B, Fodstad O, Chen J, et al. Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. *Cancer Research*. 2011; 71: 4585-4597.
36. Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, Fodstad O, Riker AI, Kamarajugadda S, Lu J, Owen LB, Ledoux SP, Tan M. Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to Taxol. *Molecular Cancer*. 2010; 9: 33.
37. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P. Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. *Cancer Research*. 2005; 65: 613-621.
38. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. *Cell Death and Disease*. 2013; 4: e532.
39. Butler EB, Zhao Y, Muñoz-Pinedo C, Lu J, Tan M. Stalling the engine of resistance: Targeting cancer metabolism to overcome therapeutic resistance. *Cancer Research*. 2013; 73: 2709-2717.
40. Xintaropoulou C, Ward C, Wise A, Marston H, Turnbull A, Langdon SP. A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models. *Oncotarget*. 2015; 6: 25677-25695.

41. Faratian D, Um I, Wilson DS, Mullen P, Langdon SP, Harrison DJ. Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy. *European Journal of Cancer*. 2011; 47: 1420-1431.
42. Lubbock ALR, Katz E, Harrison DJ, Overton IM. TMA Navigator: network inference, patient stratification and survival analysis with tissue microarray data. *Nucl. Acids Res*. 2013; 41: W562–W568.
43. Best DJ, Roberts DE. Algorithm AS 89: The Upper Tail Probabilities of Spearman's Rho. *Journal of the Royal Statistical Society. Series C (App Stat)*. 1975; 24: 377-379.
44. Mitra A, Davis DA, Tomar S, et al. In vivo tumor growth of high-grade serous ovarian cancer cell lines. *Gynecologic oncology*. 2015; 138: 372-377.
45. Provencher DM, Lounis H, Champoux L, Tétrault M, Manderson EN, Wang JC, Eydoux P, Savoie R, Tonin PN, Mes-Masson AM. Characterization of four novel epithelial ovarian cancer cell lines. *In Vitro Cell Dev Biol Anim*. 2000; 36: 357-361.
46. Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP, Schol DJ, Hilgers J, Leonard RCF, Smyth JF. Characterization and properties of nine human ovarian adenocarcinoma cell lines. *Cancer Research*. 1988; 48: 6166-6172.
47. Cooke SL, Ng CKY, Melnyk N, Garcia MJ, Hardcastle T, Temple J, Langdon S, Huntsman D, Brenton JD. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. *Oncogene*. 2010; 29: 4905-4913.
48. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. *Nat. Protocols*. 2006; 1: 1112-1116.
49. <https://patents.google.com/patent/WO2014187922A1/en>.
50. Irene V. Bijnsdorp EG, and Godefridus J. Peters, Analysis of Drug Interactions, in *Cancer Cell Culture, Methods and Protocols*, I.A. Cree, Editor 2011: Humana Press. p. 421 - 434.
51. Camp RL, Dolled-Filhart M, and Rimm DL. X-Tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization. *Clin Cancer Res*. 2004; 10: 7252 – 7259.
52. Adams DJ, Ito D, Rees MG, Seashore-Ludlow B, Puyang X, Ramos AH, Cheah JH, Clemons PA, Warmuth M, Zhu P, Shamji AF, Schreiber SL. NAMPT Is the Cellular Target of STF-31-Like Small-Molecule Probes. *ACS Chem. Biol*. 2014; 9 :2247–2254.
53. Cantuaria G, Magalhaes A, Penalver M, Angioli R, Braunschweiger P, Gomez-Marin O, Kanhoush R, Gomez-Fernandez C, Nadji M. Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary. *Gynecologic Oncology*. 2000; 79: 33-37.

54. Kalir T, Wang BY, Goldfischer M, Haber RS, Reder I, Demopoulos R, Cohen CJ, Burstein DE. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia. *Cancer*. 2002; 94: 1078-1082.
55. Rudlowski C, Moser M, Becker AJ, Rath W, Buttner R, Schroder W, Schurmann A. GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer. *Oncology*. 2004; 66: 404-410.
56. Tsukioka M, Matsumoto Y, Noriyuki M, Yoshida C, Nobeyama H, Yoshida H, Yasui T, Sumi T, Honda KI, Ishiko O. Expression of glucose transporters in epithelial ovarian carcinoma: Correlation with clinical characteristics and tumor angiogenesis. *Oncology Reports*. 2007; 18: 361-367.
57. Semaan A, Munkarah AR, Arabi H, Bandyopadhyay S, Seward S, Kumar S, Qazi A, Hussein Y, Morris RT, Ali-Fehmi R. Expression of GLUT-1 in epithelial ovarian carcinoma: Correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction. *Gynecologic Oncology*. 2011; 121: 181-186.
58. Cho H, Lee YS, Kim J, Chung JY, Kim JH. Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer. *Cancer Investigation*. 2013; 31: 607-615.
59. Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadji M, Angioli R, Penalver M, Mancuso S, Scambia G. GLUT-1 expression in ovarian carcinoma: Association with survival and response to chemotherapy. *Cancer*. 2001; 92: 1144-1150.
60. Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, Yonekura Y, Kotsuji F. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. *International Journal of Cancer*. 2004; 109: 926-932.
61. Jin Z, Gu J, Xin X, Li Y, Wang H. Expression of hexokinase 2 in epithelial ovarian tumors and its clinical significance in serous ovarian cancer. *European Journal of Gynaecological Oncology*. 2014; 35: 519-524.
62. Suh DH, Kim MA, Kim H, Kim MK, Kim HS, Chung HH, Kim YB, Song YS. Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. *Clinical and Experimental Medicine*. 2014; 14: 345-353.
63. Gerich JE. Control of glycaemia. *Bailliere's Clinical Endocrinology and Metabolism*. 1993; 7: 551-586.
64. Birsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, Yucel B, Wang T, Chen WW, Clish CB, Sabatini DM. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. *Nature*. 2014; 508: 108-112.

65. Mathews EH, Stander BA, Joubert AM, Liebenberg L. Tumor cell culture survival following glucose and glutamine deprivation at typical physiological concentrations. *Nutrition*. 2014; 30: 218-227.
66. Aykin-Burns N, Ahmad IM, Zhu Y, Oberley LW, Spitz DR. Increased levels of superoxide and H₂O₂ mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. *Biochemical Journal*. 2009; 418: 29-37.
67. Graham NA, Tahmasian M, Kohli B, Komisopoulou E, Zhu M, Vivanco I, Teitell MA, Wu H, Ribas A, Lo RS, Mellinghoff IK, Mischel PS, Graeber TG. Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. *Molecular Systems Biology*. 2012; 8: 859.
68. Bhattacharya B, Low SHH, Soh C, Kamal Mustapa N, Beloueche-Babari M, Koh KX, Loh J, Soong R. Increased drug resistance is associated with reduced glucose levels and an enhanced glycolysis phenotype. *British Journal of Pharmacology*. 2014; 171: 3255-3267.
69. Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: Molecular mechanisms of action. *European Journal of Pharmacology*. 2014; 740: 364-378.
70. Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, Hines J, Chen X. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. *Molecular Cancer Therapeutics*. 2012; 11: 1672-1682.
71. Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P, Zheng X, Sadee W, Sun D. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. *Cancer Chemotherapy and Pharmacology*. 2007; 59: 495-505.
72. Nakano A, Tsuji D, Miki H, Cui Q, El Sayed SM, Ikegame A, Oda A, Amou H, Nakamura S, Harada T, Fujii S, Kagawa K, Takeuchi K, et al. Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. *PLoS ONE*. 2011; 6: e27222.
73. Morales DR, Morris AD, *Metformin in cancer treatment and prevention*, in *Annual Review of Medicine* 2015. p. 17-29.
74. Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. Repositioning metformin for cancer prevention and treatment. *Trends in Endocrinology and Metabolism*. 2013; 24: 469-480.
75. Rizos CV, Elisaf MS. Metformin and cancer. *European Journal of Pharmacology*. 2013; 705: 96-108.

76. Coperchini F, Leporati P, Rotondi M, Chiovato L. Expanding the therapeutic spectrum of metformin: From diabetes to cancer. *Journal of Endocrinological Investigation*. 2015; 38: 1047-1055.
77. Chae YK, Arya A, Malecek MK, Shin DS, Carneiro B, Chandra S, Kaplan J, Kalyan A, Altman JK, Platanias L, Giles F. Repurposing metformin for cancer treatment: current clinical studies. *Oncotarget*. 2016; 7 40767-40780.
78. Heckman-Stoddard BM, Gandini S, Puntoni M, Dunn BK, Decensi A, Szabo E. Repurposing old drugs to chemoprevention: The case of metformin. *Seminars in Oncology*. 2016; 43: 123-133.
79. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. *Xenobiotica*. 1994; 24: 49-57.
80. Zordoky BNM, Bark D, Soltys CL, Sung MM, Dyck JRB. The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: Implications for cancer therapy and prevention. *Biochimica et Biophysica Acta - General Subjects*. 2014; 1840: 1943-1957.

Table 1. IC₅₀ concentrations for glycolysis inhibitors against the PEA1/PEA2 and PE01/PE04 pairs of HGSOC cell lines.

IC50 values	1 st pair		2 nd pair	
	PEA1	PEA2	PEO1	PEO4
IOM-1190 (μM)	0.28	0.46	4.8	1.6

STF31 (μM)	0.86	1.3	1.5	0.88
3PO (μM)	6.3	11.9	3	6.8
Oxamic acid (mM)	16	17.6	3.8	10.1

Figure Legends

Figure 1. A-D. Representative immunofluorescence images showing GLUT1, HKII, PKM2 and LDHA expression in TMA cores of ovarian cancers. **E.** Immunofluorescence images showing expression of four glycolytic enzymes in TMA cores of an individual ovarian cancer patient. Blue colour visualises DAPI nuclear counterstain, green colour cytokeratin tumour mask and red colour target staining. Quantified target expression (AQUA value) in the cytoplasmic compartment of each core is indicated.

Figure 2. Expression levels of four glycolytic enzymes in different histological subtypes of ovarian cancer. AQUA levels of GLUT1, HKII, PKM2 and LDHA are shown. Values were measured as described in Methods section. The boxplot shows the median value, with the rectangle representing the 2nd and 3rd quartiles. Statistical significance indicated (Student's t-test).

Figure 3. Expression levels of four glycolytic enzymes in different stages of ovarian cancer. AQUA levels of GLUT1, HKII, PKM2 and LDHA are shown. Values were measured as described in Methods section. The boxplot shows the median value, with the rectangle representing the 2nd and 3rd quartiles.

Figure 4. Heatmap and correlation network analysis of the expression of four glycolytic enzymes in a cohort of 380 ovarian cancers. **A.** Heatmap showing the positive Spearman rho correlation values displayed in bright yellow colours and the negative Spearman rho correlation values in dark blue colours. The heatmap was generated using TMA Navigator [42]. **B:** Spearman correlation network of the four glycolytic enzymes in the cohort. Statistically significant correlations thresholded at FDR $P < 0.01$ are presented. High number of significant connections is displayed in bright yellow colours while low in dark blue colours. Positive relationships are indicated in grey while negative in red. Thickness of connection lines reflects significance (the adjusted P value). The network was generated using TMA Navigator [42].

Figure 5: Growth response of a panel of four ovarian cancer cell lines in the presence of varying concentrations of glucose. Glucose concentrations between 0 and 25.6mM were evaluated and cells grown for a 5-day period. Optical density was determined by an SRB assay. Mean results of 6 replicates are reported and error bars represent standard deviations. Faint coloration at the bottom of the columns represents OD value on the day of treatment (Day 0). Statistical significance indications: ns not significant $P > 0.05$, * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ compared with the mean of the depleted controls (one-way ANOVA followed by Tukey-Kramer multiple comparisons test).

Figure 6: Growth response curves of ovarian cancer cell line pairs treated with glycolysis inhibitors. IOM-1190 was used at concentrations between 0.2-100 μ M, STF31 and 3PO at concentrations between 0.06-30 μ M and oxamic acid at concentrations between 0.4-100mM for a 4-day period. Cell viability was determined by an SRB assay. Mean results of 6 replicates are reported and error bars represent standard deviations. Values are shown as a percentage of control. A constant 1% DMSO concentration was used across the whole curve for IOM-1190 and a respective constant 0.3% DMSO concentration for STF31 and 3PO. IC₅₀ concentrations are listed in Table 1.

Figure 7: Growth response curves of PEA1 and PEA2 ovarian cancer cells treated with combinations of glycolysis inhibitors with chemotherapy or metformin. **A.** 3PO with cisplatin.


3PO concentrations between 0.5-30 μ M alone (blue line) or combined with a constant concentration of cisplatin (red line) were evaluated. In green the effect of 1 μ M (PEA1) or 4 μ M (PEA2) cisplatin on cell viability is presented. **B.** 3PO with paclitaxel. 3PO concentrations between 0.5-30 μ M alone (blue line) or combined with a constant concentration of paclitaxel (red line) were evaluated. In green the effect of 1 μ M (PEA1) or 2 μ M (PEA2) paclitaxel on cell viability is presented. **C.** STF31 with metformin. Concentration response curves of PEA1 and PEA2 ovarian cancer cells treated with STF31 concentrations between 0.5-30 μ M alone (blue line) or combined with 1mM metformin (red line). In green the effect of 1mM metformin on cell viability is presented. **D.** Oxamic acid with metformin. Concentration response curves of PEA1 and PEA2 ovarian cancer cells treated with oxamic acid concentrations between 1.56-100mM alone (blue line) or combined with 1mM metformin (red line). In green the effect of 1mM metformin on cell viability is presented. Cell viability was determined by an SRB assay after a 3-day treatment. Mean results of 6 replicates are reported and error bars represent standard deviations. Values are shown as a percentage of control. Asterisks indicate synergistic combination points with *CI value lower than 0.8 and **CI value lower than 0.3.

Supplementary Figure 1: Growth response curves of PE01 and PE04 ovarian cancer cells treated with combinations of glycolysis inhibitors with chemotherapy or metformin. **A.** 3PO with cisplatin. 3PO concentrations between 0.5-30 μ M alone (blue line) or combined with a constant concentration of cisplatin (red line) were evaluated. In green the effect of 0.5 μ M (PE01) or 1 μ M (PE04) cisplatin on cell viability is presented. **B.** 3PO with paclitaxel. 3PO concentrations between 0.5-30 μ M alone (blue line) or combined with a constant concentration of paclitaxel (red line) were evaluated. In green the effect of 2 μ M paclitaxel (both PE01 and PE04) on cell viability is presented. **C.** Oxamic acid with metformin. Concentration response curves of PE01 and PE04 ovarian cancer cells treated with oxamic acid concentrations between 1.56-100mM alone (blue line) or combined with 2mM (PE01) or 0.5mM (PE04) metformin (red line). In green the effect of 2mM (PE01) or 0.5mM (PE04) mM metformin on cell viability is presented. Cell viability was determined by an SRB assay after a 3-day treatment. Mean results of 6 replicates are reported and error bars represent standard deviations. Values are shown as a percentage of control. Asterisks indicate synergistic combination points with * CI value lower than 0.8 and ** CI value lower than 0.3.


Additional File 1. TMA dataset. Mean AQUA expression values for GLUT1, LDHA, HKII and PKM2 in 380 ovarian cancer samples. Histology and stage are shown for individual tumours.

Figure 1


A. GLUT1




D. LDHA



B. HKII



E.



C. PKM2



Figure 2




Figure 3




Figure 4




Figure 5




Figure 6






Figure 7



Supplementary Figure 1



Supplementary Table 1: Number of ovarian cancer samples analysed by histology and stage.

Histology	HGSOC	Endometrioid	Clear cell	Mucinous	LGSOC
	282	55	25	10	8
Stage	I	II	III	IV	Unknown
	39	43	219	66	13

HGSOC refers to high grade serous ovarian cancer, while LGSOC refers to low grade serous ovarian cancer.

Supplementary Table 2: Spearman correlation of the expression of four glycolytic enzymes in a cohort of 380 ovarian cancers. Spearman rho correlation values (top value) along with the respective adjusted P value (bottom value) of statistically significant correlations thresholded at FDR $P < 0.01$ are summarised.

Nonparametric Correlation	GLUT1	HKII	PKM2	LDHA
GLUT1	*	0.202 0.007	0.269 0.0002	0.234 0.002
HKII	0.202 0.007	*	0.340 0.000002	-
PKM2	0.269 0.0002	0.340 0.0000025	*	0.456 $5.02e^{-12}$
LDHA	0.234 0.002	-	0.456 $5.02e^{-12}$	*